ANI Pharmaceuticals, Inc. (ANIP)
USD 68.82
(1.03%)
USD 68.82
(1.03%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 94.2 Million USD | -60.47% |
| 2022 | 238.29 Million USD | 27.38% |
| 2021 | 187.07 Million USD | 5.2% |
| 2020 | 177.82 Million USD | 44.08% |
| 2019 | 123.41 Million USD | -11.85% |
| 2018 | 140 Million USD | -17.82% |
| 2017 | 170.36 Million USD | 82.64% |
| 2016 | 93.27 Million USD | 326.09% |
| 2015 | -41.25 Million USD | 29.29% |
| 2014 | -58.34 Million USD | -425.4% |
| 2013 | -11.1 Million USD | 58.73% |
| 2012 | -26.91 Million USD | 32.54% |
| 2011 | -39.88 Million USD | -103.43% |
| 2010 | -19.6 Million USD | -48.75% |
| 2009 | -13.18 Million USD | -12.08% |
| 2008 | -11.76 Million USD | 24.85% |
| 2007 | -15.64 Million USD | -104.46% |
| 2006 | -7.65 Million USD | -2363.87% |
| 2005 | -310.64 Thousand USD | 73.45% |
| 2004 | -1.17 Million USD | 87.19% |
| 2003 | -9.13 Million USD | -87.04% |
| 2002 | -4.88 Million USD | -8.47% |
| 2001 | -4.5 Million USD | -113.21% |
| 2000 | -2.11 Million USD | 59.96% |
| 1999 | -5.27 Million USD | -85.64% |
| 1998 | -2.84 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 69.98 Million USD | -14.35% |
| 2024 Q1 | 81.71 Million USD | -13.27% |
| 2023 Q4 | 94.2 Million USD | 1.51% |
| 2023 Q3 | 92.8 Million USD | -25.39% |
| 2023 FY | 94.2 Million USD | -60.47% |
| 2023 Q1 | 218.55 Million USD | -8.28% |
| 2023 Q2 | 124.38 Million USD | -43.09% |
| 2022 Q3 | 230.45 Million USD | 3.08% |
| 2022 FY | 238.29 Million USD | 27.38% |
| 2022 Q1 | 210.24 Million USD | 12.39% |
| 2022 Q2 | 223.56 Million USD | 6.33% |
| 2022 Q4 | 238.29 Million USD | 3.4% |
| 2021 Q4 | 187.07 Million USD | 0.18% |
| 2021 FY | 187.07 Million USD | 5.2% |
| 2021 Q3 | 186.73 Million USD | 3.49% |
| 2021 Q2 | 180.44 Million USD | 13.95% |
| 2021 Q1 | 158.35 Million USD | -10.95% |
| 2020 Q2 | 162.5 Million USD | -9.49% |
| 2020 Q4 | 177.82 Million USD | 4.57% |
| 2020 Q3 | 170.04 Million USD | 4.64% |
| 2020 FY | 177.82 Million USD | 44.08% |
| 2020 Q1 | 179.55 Million USD | 45.48% |
| 2019 Q4 | 123.41 Million USD | -2.78% |
| 2019 FY | 123.41 Million USD | -11.85% |
| 2019 Q2 | 145.1 Million USD | -0.38% |
| 2019 Q1 | 145.66 Million USD | 4.04% |
| 2019 Q3 | 126.94 Million USD | -12.52% |
| 2018 Q2 | 149.61 Million USD | -0.63% |
| 2018 FY | 140 Million USD | -17.82% |
| 2018 Q4 | 140 Million USD | -13.38% |
| 2018 Q3 | 161.63 Million USD | 8.03% |
| 2018 Q1 | 150.56 Million USD | -11.62% |
| 2017 FY | 170.36 Million USD | 82.64% |
| 2017 Q4 | 170.36 Million USD | 27.85% |
| 2017 Q3 | 133.25 Million USD | -8.74% |
| 2017 Q2 | 146.01 Million USD | 3.06% |
| 2017 Q1 | 141.67 Million USD | 51.88% |
| 2016 Q4 | 93.27 Million USD | -9.13% |
| 2016 Q2 | 101.97 Million USD | 172.29% |
| 2016 FY | 93.27 Million USD | 326.09% |
| 2016 Q1 | 37.45 Million USD | 190.78% |
| 2016 Q3 | 102.65 Million USD | 0.66% |
| 2015 FY | -41.25 Million USD | 29.29% |
| 2015 Q1 | -53.39 Million USD | 8.49% |
| 2015 Q4 | -41.25 Million USD | -15.5% |
| 2015 Q3 | -35.72 Million USD | 32.68% |
| 2015 Q2 | -53.05 Million USD | 0.62% |
| 2014 Q2 | -52.96 Million USD | -3.09% |
| 2014 Q4 | -58.34 Million USD | -66.47% |
| 2014 Q3 | -35.05 Million USD | 33.82% |
| 2014 Q1 | -51.37 Million USD | -362.61% |
| 2014 FY | -58.34 Million USD | -425.4% |
| 2013 Q3 | -10.92 Million USD | 13.22% |
| 2013 Q1 | -21.21 Million USD | 21.15% |
| 2013 Q4 | -11.1 Million USD | -1.6% |
| 2013 FY | -11.1 Million USD | 58.73% |
| 2013 Q2 | -12.59 Million USD | 40.64% |
| 2012 Q4 | -26.91 Million USD | 11.64% |
| 2012 Q1 | -38.98 Million USD | 2.28% |
| 2012 FY | -26.91 Million USD | 32.54% |
| 2012 Q2 | -31.93 Million USD | 18.06% |
| 2012 Q3 | -30.45 Million USD | 4.64% |
| 2011 FY | -39.88 Million USD | -103.43% |
| 2011 Q4 | -39.88 Million USD | 18.8% |
| 2011 Q3 | -49.12 Million USD | -182.74% |
| 2011 Q2 | -17.37 Million USD | 45.98% |
| 2011 Q1 | -32.16 Million USD | -64.03% |
| 2010 Q3 | -17.16 Million USD | 38.52% |
| 2010 Q1 | -23.07 Million USD | -75.07% |
| 2010 FY | -19.6 Million USD | -48.75% |
| 2010 Q2 | -27.91 Million USD | -20.96% |
| 2010 Q4 | -19.6 Million USD | -14.25% |
| 2009 FY | -13.18 Million USD | -12.08% |
| 2009 Q1 | -10.16 Million USD | 13.59% |
| 2009 Q2 | -5.98 Million USD | 41.1% |
| 2009 Q3 | -13.16 Million USD | -120.01% |
| 2009 Q4 | -13.18 Million USD | -0.1% |
| 2008 Q4 | -11.76 Million USD | -106.31% |
| 2008 Q3 | -5.7 Million USD | 44.79% |
| 2008 Q2 | -10.32 Million USD | 21.22% |
| 2008 FY | -11.76 Million USD | 24.85% |
| 2008 Q1 | -13.1 Million USD | 16.25% |
| 2007 Q2 | -27.38 Million USD | -142.52% |
| 2007 Q4 | -15.64 Million USD | 38.4% |
| 2007 FY | -15.64 Million USD | -104.46% |
| 2007 Q1 | -11.29 Million USD | -47.52% |
| 2007 Q3 | -25.4 Million USD | 7.23% |
| 2006 FY | -7.65 Million USD | -2363.87% |
| 2006 Q4 | -7.65 Million USD | -1990.22% |
| 2006 Q3 | -366.17 Thousand USD | -174.07% |
| 2006 Q2 | -133.6 Thousand USD | -90.35% |
| 2006 Q1 | -70.18 Thousand USD | 77.41% |
| 2005 Q4 | -310.64 Thousand USD | -22.23% |
| 2005 Q1 | -56.18 Thousand USD | 95.2% |
| 2005 Q2 | -379.52 Thousand USD | -575.55% |
| 2005 FY | -310.64 Thousand USD | 73.45% |
| 2005 Q3 | -254.14 Thousand USD | 33.04% |
| 2004 FY | -1.17 Million USD | 87.19% |
| 2004 Q4 | -1.17 Million USD | 94.31% |
| 2004 Q1 | -8.26 Million USD | 9.55% |
| 2004 Q3 | -20.57 Million USD | 10.43% |
| 2004 Q2 | -22.97 Million USD | -178.04% |
| 2003 Q1 | -3.41 Million USD | 30.14% |
| 2003 FY | -9.13 Million USD | -87.04% |
| 2003 Q3 | -10.39 Million USD | -345.24% |
| 2003 Q4 | -9.13 Million USD | 12.14% |
| 2003 Q2 | -2.33 Million USD | 31.56% |
| 2002 Q3 | 28.22 Million USD | -52.61% |
| 2002 Q2 | 59.57 Million USD | 23.69% |
| 2002 FY | -4.88 Million USD | -8.47% |
| 2002 Q1 | 48.16 Million USD | 141.52% |
| 2002 Q4 | -4.88 Million USD | -117.3% |
| 2001 Q2 | -4.28 Million USD | 9.32% |
| 2001 Q3 | 21.42 Million USD | 600.27% |
| 2001 Q4 | 19.94 Million USD | -6.91% |
| 2001 FY | -4.5 Million USD | -113.21% |
| 2001 Q1 | -4.72 Million USD | -123.6% |
| 2000 Q3 | -2.73 Million USD | 18.75% |
| 2000 FY | -2.11 Million USD | 59.96% |
| 2000 Q1 | -4.81 Million USD | 0.0% |
| 2000 Q2 | -3.36 Million USD | 30.06% |
| 2000 Q4 | -2.11 Million USD | 22.79% |
| 1999 FY | -5.27 Million USD | -85.64% |
| 1998 FY | -2.84 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 78.36% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 79.462% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 702.553% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 702.553% |
| SCYNEXIS, Inc. | -19.35 Million USD | 586.858% |
| Safety Shot Inc | -2.28 Million USD | 4223.973% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 1099.042% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 78.23% |
| PainReform Ltd. | -7.95 Million USD | 1284.994% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -25.693% |
| Cosmos Health Inc. | 8.59 Million USD | -996.609% |
| Journey Medical Corporation | -9.7 Million USD | 1070.306% |
| Dynavax Technologies Corporation | 106.63 Million USD | 11.655% |
| Embecta Corp. | 1.31 Billion USD | 92.82% |
| Alpha Teknova, Inc. | 1.97 Million USD | -4672.391% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 172.008% |
| Bright Green Corporation | 1.84 Million USD | -5015.153% |
| Procaps Group, S.A. | 242.93 Million USD | 61.221% |
| Theratechnologies Inc. | 24.87 Million USD | -278.783% |
| Harrow Health, Inc. | 116.41 Million USD | 19.078% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 3838.373% |
| Biofrontera Inc. | 4.05 Million USD | -2222.658% |
| DURECT Corporation | -7.65 Million USD | 1330.82% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 380.988% |
| Cronos Group Inc. | -663.32 Million USD | 114.202% |
| OptiNose, Inc. | 58.06 Million USD | -62.244% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 84.888% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 746.493% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 1916.553% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -527.503% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 1581.325% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -88060.099% |
| Radius Health, Inc. | 359.28 Million USD | 73.779% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -47670.132% |
| ProPhase Labs, Inc. | 19.23 Million USD | -389.871% |
| Phibro Animal Health Corporation | 454.84 Million USD | 79.288% |
| Procaps Group S.A. | 242.93 Million USD | 61.221% |
| Alvotech | 1.06 Billion USD | 91.149% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -2461.365% |
| Viatris Inc. | 17.13 Billion USD | 99.45% |
| Rockwell Medical, Inc. | 4.45 Million USD | -2014.161% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 2031.659% |
| SIGA Technologies, Inc. | -148.68 Million USD | 163.361% |
| Tilray Brands, Inc. | 158.97 Million USD | 40.742% |
| Lifecore Biomedical, Inc. | 121.89 Million USD | 22.717% |
| Shineco, Inc. | 29.29 Million USD | -221.632% |
| PetIQ, Inc. | 351.93 Million USD | 73.232% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 3346.918% |
| Incannex Healthcare Limited | -5.48 Million USD | 1817.539% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 46.866% |
| Alimera Sciences, Inc. | 55.3 Million USD | -70.329% |
| Silver Spike Investment Corp. | -32.61 Million USD | 388.875% |
| Assertio Holdings, Inc. | -32.52 Million USD | 389.609% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 6428.045% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 1961.657% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 2056.938% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1246.981% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -2133.982% |
| Hempacco Co., Inc. | 13.61 Million USD | -591.952% |
| Talphera, Inc. | -5.72 Million USD | 1746.688% |
| Alvotech | 1.06 Billion USD | 91.149% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -1218.502% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 197.412% |
| Currenc Group, Inc. | -16.57 Million USD | 668.432% |
| Kamada Ltd. | -46.43 Million USD | 302.894% |
| Indivior PLC | -33.95 Million USD | 377.471% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -36053.645% |
| Flora Growth Corp. | -713 Thousand USD | 13312.763% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1246.981% |
| Evolus, Inc. | 63.7 Million USD | -47.873% |
| HUTCHMED (China) Limited | -197.45 Million USD | 147.71% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 80.337% |
| Akanda Corp. | 3.9 Million USD | -2312.523% |